Evidence map›Paper›PMID 39581846›Full record

ArticleJournal of the International AIDS Society2024

Increasing event-driven HIV pre-exposure prophylaxis use among gay, bisexual and other men who have sex with men in Australia: results from behavioural surveillance 2019-2023.

Curtis Chan, Martin Holt, Anthony K J Smith, Timothy R Broady, James MacGibbon, Limin Mao, Ben Wilcock, John Rule, Benjamin R Bavinton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Curtis ChanKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9581-1011
Martin HoltCentre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2586-8274
Anthony K J SmithCentre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-0005-9542
Timothy R BroadyCentre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-4341-1868
James MacGibbonCentre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-1359-9572
Limin MaoCentre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-0995-5789
Ben WilcockHealth Equity Matters, Sydney, New South Wales, Australia.
John RuleNational Association of People with HIV Australia, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7518-7744
Benjamin R BavintonKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5834-8278

Funding

Australian Government Department of Health and state/territory health departmentsNational Health and Medical Research Council Partnership Project GNT2002625
6 · The paper itself

Abstract

introductionHIV pre-exposure prophylaxis (PrEP) has been publicly available since 2018 in Australia as a daily regimen. In 2019, clinical guidelines were updated to support guidance on event-driven PrEP (ED-PrEP) use. We assessed trends in the PrEP dosing regimen by comparing daily PrEP use to ED-PrEP among cisgender gay, bisexual and other men who have sex with men (GBMSM).

methodsData from repeated, cross-sectional, national behavioural surveillance surveys were analysed from 2019 to 2023 among participants not living with HIV. Logistic regression models were conducted to assess trends and compared ED-PrEP users to non-PrEP users and daily PrEP.

resultsAmong 38,880 participants, overall PrEP use with any regimen increased from 27.6% in 2019 to 42.7% in 2023 (OR = 1.16, 95% CI = 1.15-1.18, p < 0.001). Among 12,922 participants who reported PrEP use in the last 6 months, the proportion reporting ED-PrEP use increased from 7.6% in 2019 to 27.8% in 2023 (OR = 1.41, 95% CI = 1.37-1.46, p < 0.001) with those who reported daily PrEP decreasing from 92.4% to 63.3% (OR = 0.64, 95% CI = 0.62-0.66, p < 0.001). In a cross-sectional sub-sample in 2022-2023 (n = 8840), compared to ED-PrEP users, non-PrEP users were less likely to have received three or more HIV tests in the last 12 months (aRRR = 0.26, 95% CI = 0.22-0.31, p < 0.001), have 2-10 male sexual partners in the last 6 months (aRRR = 0.24, 95% CI = 0.14-0.41, p < 0.001) or 11 or more (aRRR = 0.26, 95% CI = 0.15-0.45, p < 0.001) compared to none, or to report condomless anal intercourse with casual partners (aRRR = 0.38, 95% CI = 0.32-0.46, p < 0.001). Compared to ED-PrEP users, daily PrEP users were more likely to have received three of more HIV tests in the last year (aRRR = 3.73, 95% CI = 3.15-4.40, p < 0.001) and less likely to be born overseas and lived in Australia for less than 5 years compared to being born in Australia (aRRR = 0.64, 95% CI = 0.49-0.83, p = 0.001).

conclusionsWhile daily PrEP remains the most common PrEP dosing regimen among GBMSM in Australia, there has been a steep increase in the proportion of PrEP users who are taking ED-PrEP. Monitoring of PrEP use should continue to adapt to new dosing methods and future PrEP options. As ED-PrEP use increases, further work is needed to ensure those taking ED-PrEP are taking it effectively to prevent HIV.

Indexed as

HIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisAdolescentAdultAnti-HIV AgentsAustraliaCross-Sectional StudiesHumansMaleMiddle AgedSexual and Gender MinoritiesSexual BehaviorYoung AdultAnti-HIV Agentsevent‐driven PrEPgay and bisexual menHIV preventionmen who have sex with menon‐demand PrEPpre‐exposure prophylaxis

Identifiers

PMID39581846
PMCPMC11586104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.